Delving into the Latest Updates on Glofitamab with Synapse

Overview

Basic Info

Drug Type

Bispecific T-cell Engager (BiTE)

Synonyms

Anti-CD20/CD3 bispecific monoclonal antibody, Anti-CD20/CD3 bispecific monoclonal antibody RO7082859, Glofitamab (USAN/INN)

+ [14]

Target

CD20 x CD3

Action

inhibitors, stimulants

Mechanism

CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Diffuse large B-cell lymphoma recurrentDiffuse large B-cell lymphoma refractoryDiffuse Large B-Cell Lymphoma+ [26]

Inactive Indication-

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

Genentech, Inc.

Roche China Holding Ltd.

Hoffmann-La Roche Ltd.

+ [8]

Inactive Organization-

License Organization

Biogen, Inc.

Genentech, Inc.

Drug Highest PhaseApproved

First Approval Date

Canada (24 Mar 2023),

Diffuse Large B-Cell LymphomaFollicular LymphomaHigh grade B-cell lymphoma+ [1]

RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (Australia), Conditional marketing approval (European Union), Conditional marketing approval (Canada)

Login to view timeline

Structure/Sequence

Sequence Code 10044005

Source: *****

Sequence Code 10044025

Source: *****

Sequence Code 616723731

Source: *****

Sequence Code 616723732

Source: *****

The goal of this clinical trial is to see if a new combination of standard of care radiotherapy treatment prior to administering the study drugs obinutuzumab and glofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma patients is effective. The main question it aims to answer is:
If you are able to tolerate the study treatments, and whether your cancer responds to the study treatment, compared with other reported studies of standard care treatments.
Participants will have three parts they need to complete over a 5 year period.
* Screening period over a 28 day period
* Treatment period - Radiotherapy followed by 12 treatment cycles every three weeks (total time approx. 37 weeks)
* Follow up, up to 4 years. Additional PET imaging studies will be performed in a cohort of patients (up to 6) who are willing to undergo infusions of 89Zr-Df-Crefmirlimab and 18F-Granzyme B for evaluation of the impact of radiotherapy plus glofitamab with relapsed diffuse large B-cell lymphoma.

Start Date01 Dec 2026

Sponsor / Collaborator

Olivia Newton-John Cancer Research Institute

[+4]

NCT07444710

/ Not yet recruitingPhase 1IIT

A Phase I Study of Glofitamab With Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma

This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/ rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) for the treatment of mantle cell lymphoma. Glofitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone and dexamethasone are in a class of medications called corticosteroids. They are used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Chemotherapy drugs, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab may be safe, tolerable and/or effective in treating patients with mantle cell lymphoma.

Start Date20 Aug 2026

Sponsor / Collaborator

National Cancer Institute

NCT07003295

/ RecruitingPhase 2IIT

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells. Glofitamab is a bispecific antibody that can bind to two different antigens at the same time. Glofitamab binds to CD3, a protein found on T cells (a type of white blood cell), and CD20 a protein found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving glofitamab and obinutuzumab may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma after receiving CD19-directed CAR T-cell therapy.

Start Date14 Aug 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Glofitamab

Login to view more data

100 Translational Medicine associated with Glofitamab

Login to view more data

100 Patents (Medical) associated with Glofitamab

Login to view more data

137

Literatures (Medical) associated with Glofitamab

12 May 2026·Leukemia & Lymphoma

Glofitamab as a salvage therapy postallogenic hematopoietic stem cell transplant in relapsed-refractory Burkitt lymphoma

Article

Author: Hurst, Erin ; Collin, Matthew ; Publicover, Amy ; Jardine, Laura ; Gupta, Yashashree ; Bigley, Venetia

12 May 2026·Blood Advances

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma

Article

Author: Yángüez, Emilio ; Bottos, Alessia ; Schlenker, Ramona ; Herter, Sylvia ; Nassiri, Sina ; Umaña, Pablo ; Servera, Llucia Alberti ; Sam, Johannes ; Klein, Christian ; Bacac, Marina ; Schmeing, Stephan ; Hüsser, Tamara ; Leclercq-Cohen, Gabrielle

Abstract:

T-cell engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment. In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (peripheral blood mononuclear cells [PBMCs]) from patients with glofitamab-treated R/R B-NHL, achieving complete metabolic response, or with progressive metabolic disease. Our findings reveal that the maintenance of naïve-like (“fresher”) T-cell states (particularly the fresher cytotoxic T cells) at early time points is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared with nonresponders. Furthermore, the analysis of patient PBMCs and intratumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB costimulation translated into increased proportions of intratumor T cells having a fresher, naïve-like phenotype, ultimately leading to stronger antitumor efficacy. Taken together, our findings underscore the therapeutic relevance of fresher, naïve-like T-cell states and the potential of leveraging 4-1BB costimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.

12 May 2026·Blood Advances

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma

Article

Author: Neumann, Marie Anne-Catherine ; Schommers, Philipp ; Heger, Jan-Michel ; Schneider, Jessica ; Borchmann, Peter ; Hallek, Michael ; Borchmann, Sven ; Szameitat, Max

201

News (Medical) associated with Glofitamab

08 Jun 2026

·www.prnewswire.com

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical data for KT209, its novel trispecific antibody candidate, will be presented in a poster session at the European Hematology Association (EHA 2026) Annual Congress. KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to achieve deep B-cell depletion. While traditional bispecific T-cell engagers (TCEs) targeting a single antigen face challenges with treatment failure due to antigen escape (low or lost CD19/CD20 expression), KT209's dual-antigen targeting mechanism is designed to prevent escape and improve clinical outcomes. Enhanced by a proprietary CD3 masking design, KT209 delivers exceptional anti-tumor potency alongside a highly optimized safety profile. Presentation Details Poster Title: A NOVEL TRISPECIFIC ANTIBODY KT209 TARGETING CD19, CD20, AND CD3 (CD19XCD20XCD3) DEMONSTRATED POTENT ACTIVITY IN B-CELL DISEASES WITH LOWER CYTOKINE RELEASES Poster Number: PF369 Session: Poster Session 1 Dates: Thursday, June 11 – Friday, June 12, 2026 Highly Differentiated Preclinical Profile The upcoming poster presentation highlights comprehensive preclinical data evaluating KT209 across in vitro, in vivo, and non-human primate (NHP) models: Resistance-Proof Cytotoxicity: KT209 demonstrated robust clearance against both Raji and Nalm19 leukemia cells. Crucially, in Nalm19 models—which express low levels of CD20—the approved TCE glofitamab suffered a significant drop-off in efficacy, whereas KT209 maintained potent tumor-killing activity. Decoupling Potency from Toxicity: In head-to-head human PBMC assays, KT209 demonstrated a clear trend of lower inflammatory cytokine release compared to glofitamab, successfully mitigating the primary driver of Cytokine Release Syndrome (CRS). In Vivo Tumor Clearance: In humanized NOG mouse models, KT209 achieved potent, dose-dependent anti-leukemia activity. Favorable NHP Safety and Tolerability: In non-human primates, a single subcutaneous dose of KT209 triggered rapid and deep peripheral B-cell depletion at the lowest tested dose. The molecule was completely well-tolerated with zero clinical adverse events and only minimal, transient cytokine release restricted to the first dose. Leadership Commentary John Wang, Chief Scientific Officer of Kali Therapeutics, commented: "The data to be showcased at EHA underscores the highly differentiated profile of KT209. By integrating dual-antigen B-cell targeting with our proprietary CD3 masking technology, we have engineered a molecule that is fundamentally more potent than currently approved TCEs in low-antigen environments, yet operates with a much wider safety window. This allows us to achieve maximum tumor attrition while strictly limiting systemic cytokine release." Weihao Xu, Chief Executive Officer of Kali Therapeutics, stated: "Our presentation at EHA 2026 marks a pivotal milestone in the strategic expansion of Kali. By bringing our platform into the oncology space, we are demonstrating that our ability to safely engage T-cells is truly drug-class agnostic. The unique safety profile of our TCEs, which has already validated our autoimmune pipeline, allows us to aggressively target hematologic malignancies where tumor escape and severe CRS have historically limited patient outcomes. With KT209, we look forward to advancing into first-in-human clinical trials in Q1 2027." About KT209 KT209 is a novel CD19 x CD20 x CD3 trispecific antibody engineered using Kali's proprietary multi-specific antibody platform. It is designed to maximize therapeutic efficacy by simultaneously binding to two distinct B-cell antigens (CD19 and CD20) and co-engaging CD3 on T cells. This dual-targeting approach minimizes the risk of tumor escape while its unique CD3 masking design controls T-cell activation kinetics, reducing cytokine release syndrome (CRS) risks while enabling complete removal of pathogenic B-cell populations. About Kali Therapeutics Kali Therapeutics is a clinical-stage biotechnology company based in San Mateo, California, dedicated to developing next-generation multi-specific therapies. By leveraging proprietary antibody engineering, Kali aims to redefine the treatment landscape for patients suffering from severe autoimmune diseases and advanced hematologic malignancies. SOURCE Kali Therapeutics 21% more press release views with Request a Demo

Immunotherapy

04 Jun 2026

·www.fiercepharma.com

ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta

A 13% death rate in the study arm of a trial of ADC Therapeutics' Zynlonta have sent shares of the Swiss biotech tumbling. The FDA approved the antibody-drug conjugate in 2021 to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since the FDA granted it accelerated approval in 2021.In the phase 3 LOTIS-5 trial, which included 440 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there were 27 deaths (13.2%) in the study arm compared to nine (4.6%) in the control group. Zynlonta was paired with Roche’s monoclonal antibody Rituxan, while those in the control arm received Rituxan plus the chemotherapies gemcitabine and oxaliplatin.Most of the deaths in the treatment arm were among patients age 75 and older and were due to infections, ADC execs said on a conference call on Wednesday. The company added that the higher rate could also be chalked up to extended monitoring of patients in the treatment arm as opposed to those in the control arm.“This difference is primarily driven by a higher rate of and earlier switching to subsequent therapies in the control arm,” ADC explained in its release.In addition to the deaths, there was a higher rate of serious adverse events (SAEs) in the study arm (49%) versus the control arm (34.5%) and withdrawals from treatment in the Zynlonta arm (25.5%) versus the control arm (9.1%). The deaths, which are referred to as Grade 5 treatment emergent adverse events (TEAEs) in the company’s release, overshadowed the positive topline results from the trial, which achieved its primary endpoint of progression-free survival (6.1 months vs. 4.7 months). The Zynlonta/Rituxan combo also provided a higher complete response rate (39.5% vs. 26.7%) and a longer duration of complete response (16.8 months vs. 12.3 months). There also was no “detrimental effect” on the secondary endpoint of overall survival, ADC said. The confirmatory trial was designed to pave the way for full approval of Zynlonta and to advance it from third-line to second-line use. With the results, which were disclosed Wednesday afternoon after the market closed, ADC’s share price plummeted by 52%. Zynlonta is the Swiss company’s lone commercial product, generating sales of $74 million last year and $20 million in the first quarter of this year. ADC reported a month ago that it had $231 million in cash, with its runway extending into 2028. CEO Ameet Mallik said during the conference call that the company will meet with the FDA in August to discuss the results and its plan to submit for approval in the fourth quarter of this year.ADC also is investigating Zynlonta in the LOTIS-7 trial in combination with Roche’s bispecific antibody Columvi as a treatment for B-cell non-Hodgkin lymphoma. In a phase 1b study of the combo, there were just two deaths among 49 patients (4.1%).

Clinical ResultADCDrug ApprovalPhase 3Phase 1

03 Jun 2026

·www.fiercepharma.com

With Cencora pact, Gilead looks to grow CAR-T treatment center network

Gilead subsidiary Kite Pharma has made a deal with distribution giant Cencora that will expand its treatment center network and increase access to CAR-T therapies Yescarta and Tecartus. Pharma solutions firm Cencora and Gilead Sciences have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to Gilead's CAR-T cancer therapies Yescarta and Tecartus.The collaboration is designed to facilitate more efficient access to the blood cancer therapies, which were developed by Gilead’s CAR-T subsidiary Kite Pharma. Under the agreement, Cencora will leverage its substantial distribution infrastructure to bolster cell therapy availability at an "increasing number" of authorized U.S. treatment centers, including health systems and community oncology practices, according to a June 2 release. “Cencora has a proven track record of supporting complex therapies,” Christophe Griolet, Kite’s U.S. VP and general manager, said in a release. “As we expand our treatment center network, Cencora’s specialty distribution infrastructure and expertise will support a seamless experience across new and existing sites, reducing provider barriers and enabling us to meet patients where they are.” Since Yescarta and Novartis' Kymriah first came online in 2017, uptake of CAR-T therapies has been hindered at times by high prices, small patient pools and limited manufacturing capacity. A lack of designated treatment centers and hospital infrastructure has also limited access to CAR-Ts in the past.“Cell therapies are individualized treatments made from a patient’s own cells, and pose unique challenges to healthcare providers, including health systems and community practices,” said Melissa Lattanzi, VP of emerging therapies at Cencora, in a statement. “We will leverage our distribution infrastructure and services to support efficient access and reduce administrative burdens—including order management—across sites of care, advancing Kite’s goal to bring therapies closer to patients' homes.” Along with Texas-based McKesson and Ohio-based Cardinal Health, Cencora is one of the “Big Three” pharmaceutical distribution companies. In fiscal year 2025, Cencora reported revenue of $321 billion.Meanwhile, faced with competition from newer treatments such as Bristol Myers Squibb’s CAR-T Breyanzi and bispecific antibodies like AbbVie and Genmab’s Epkinly and Roche’s Columvi, sales of Yescarta and Tecartus declined for the first time last year. In 2025, which was the eighth full year on the market for Yescarta, the CAR-T therapy's sales declined by 5% to $1.5 billion. Tecartus, which was approved in 2020, saw a 15% sales drop-off to $344 million. For its part, BMS reported that revenue from Breyanzi increased by 82% to $1.4 billion in 2025. The treatment was approved in 2021. Sales of Epkinly and Columvi—which were greenlit in 2023—reached $468 million and $165 million, respectively.Pennsylvania-based Cencora, which was formerly known as AmeriSourceBergen, has partnered with Gilead for more than two decades. In 2020, it was the sole U.S. distributor for Gilead’s COVID-19 antiviral treatment Veklury.

Drug ApprovalCell TherapyImmunotherapyLicense out/in

100 Deals associated with Glofitamab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11833	-	-	DB16371

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diffuse large B-cell lymphoma recurrent	Canada	Hoffmann-La Roche Ltd.	25 Mar 2023
Diffuse large B-cell lymphoma refractory	Canada	Hoffmann-La Roche Ltd.	25 Mar 2023
Diffuse Large B-Cell Lymphoma	Canada	Hoffmann-La Roche Ltd.	24 Mar 2023
Follicular Lymphoma	Canada	Hoffmann-La Roche Ltd.	24 Mar 2023
High grade B-cell lymphoma	Canada	Hoffmann-La Roche Ltd.	24 Mar 2023
Mediastinal large B-cell lymphoma	Canada	Hoffmann-La Roche Ltd.	24 Mar 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mantle-Cell Lymphoma	Phase 3	United States	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	China	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Australia	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Brazil	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Canada	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	France	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Italy	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	South Korea	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Spain	Roche Holding AG	22 Oct 2023
Mantle-Cell Lymphoma	Phase 3	Sweden	Roche Holding AG	22 Oct 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Diffuse large B-cell lymphoma recurrent	410	epcoritamab	rqwcevsgsl(kqdtycqtow) = 19.0% vs 25.4% nwscolkfgw (twtapqcvzu ) View more	Positive	29 May 2026
				glofitamab
ASCO2026	Not Applicable	Diffuse Large B-Cell Lymphoma	936	CAR T-cell therapy	hvaevkbluu(hpyacuvhcp) = qeqcposiwl ekfucaszrn (rkhgpqqpdk ) View more	Positive	29 May 2026
				Bispecific antibodies	hvaevkbluu(hpyacuvhcp) = agdhnkqqaa ekfucaszrn (rkhgpqqpdk ) View more
NCT03075696 (ASCO2026)	Phase 1/2	Mantle-Cell Lymphoma	60	Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamab + Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamabab 1000mg + Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamabab 2000mg	qrnbgmibuu(ytkqizskkc) = eslrlwrxub txrytouzku (fidwhbmucw ) View more	Positive	29 May 2026
				Obinutuzumab 2000mg (prior BTKi therapy)	qrnbgmibuu(ytkqizskkc) = utdjfeihfz txrytouzku (fidwhbmucw ) View more
ASCO2026	Not Applicable	B-Cell Lymphoma	63	Glofitamab	pptilmrvzw(oudnuitgnz) = gdkaazdkhm ustovgtpfj (zubcpyxqjy ) View more	Positive	29 May 2026
				Epcoritamab	pptilmrvzw(cnojkspner) = lijrlswtjt atykhpmyyw (bhayyndwrd ) View more
NCT06393738 (ASCO2026)	Phase 1	Non-Hodgkin Lymphoma \| Diffuse Large B-Cell Lymphoma	255	ARV-393 (relapsed or refractory B-cell NHL or nTFHL)	fbopexswva(bgtnvouzjm) = uargcizxcv smaspfltld (ppsylidxgo )	Positive	29 May 2026
ASCO2026	Not Applicable	Acute Lymphoblastic Leukemia \| Small Cell Carcinoma \| B-Cell Lymphoma ... View more	3,642	bispecific T-cell engager therapy	stgwufatgf(sdlzbwbrlz) = frqtdixxej inumljtjhq (tlvcbbuosy ) View more	Positive	29 May 2026
NCT06393738 (AACR2026)	Phase 1	Diffuse Large B-Cell Lymphoma \| Non-Hodgkin Lymphoma	255	ARV-393 (NHL)	cebgltjyik(glejoxbyfm) = The most common ≥Grade 3 AEs were neutropenia (54.2% [ARV-393] and 63.0% [ARV-393 + glofitamab]), anemia (9.1% and 15.6%), and thrombocytopenia (9.1% and 15.6%) hheaxesofg (dgzxjdoscj ) View more	Positive	21 Apr 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Solid tumor \| Hematologic Neoplasms	61	Bispecific Therapies	liyrhnqxrx(gaxaatyzwc) = gkubbetqyr biquydzuok (hfmjwgbqou ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Mantle-Cell Lymphoma	20	Mosunetuzumab (mosun) + Polatuzumab (pola)	gkcwzotdfn(qphcqamxsp) = pnwghimfun ziqqrvglhl (ykbvkxzwrd ) View more	Positive	04 Feb 2026
				Glofitamab (glofit)	gkcwzotdfn(qphcqamxsp) = zzlwmjeufc ziqqrvglhl (ykbvkxzwrd ) View more
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	B-Cell Lymphoma	16	glofitamabmosunetuzumabepcoritamab + glofitamabmosunetuzumabepcoritamab + glofitamabmosunetuzumabepcoritamabab	ejmzgkyipz(djcpwrquyj) = fllrwfhglx hsdbjfwlvb (bjsqnhwaac, 200 - 25,970) View more	Positive	04 Feb 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Glofitamab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation